What You Should Know:
- Prenosis, Inc., a Chicago, IL-based AI company enabling precision medicine in acute care, announced today that it has been awarded two Phase 2 SBIR grants totaling $4.8M in funding by the National Institute of General Medical Sciences (NIGMS), a division of the National Institute of Health (NIH).
- The grants will study the use of Prenosis’s Immunix™ Artificial Intelligence platform for acute immune states. Prenosis has built a collection of artificial intelligence algorithms, broad clinical data, deep biological data, and biobanked samples of patients suspected of sepsis, in addition to detailed information about their treatment regime. The goal is to better understand how patients’ health states rapidly evolve in acute care environments.
- The grants are titled “Combined Biomarker and EMR Data for Heterogeneous Treatment Effects and Surrogate Endpoints in Sepsis”, and “Use of Time Series Biomarker and Clinical Data to Construct a Time Trajectory Host Response Map”.
